Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms
Gabriele Todisco(Humanitas University), Eva Hellström Lindberg(Karolinska Institutet), Francesca Ficara(Humanitas University), Bianca Tesi(Karolinska University Hospital), Elli Papaemmanuil, Alessia Campagna(Humanitas University), Elsa Bernard(Inserm), Indira Barbosa(Karolinska Institutet), Matteo Zampini(IRCCS Humanitas Research Hospital), Pedro Luís Moura(Integrated Cardio Metabolic Centre), Maria Creignou(Karolinska University Hospital), Matteo Della Porta(University of Milan), Teresa Mortera‐Blanco(Karolinska University Hospital), Marta Ubezio(Humanitas University), Magnus Tobiasson(Karolinska University Hospital), Alessandro Buizza(IRCCS Humanitas Research Hospital), Armando Santoro(IRCCS Humanitas Research Hospital), Ann‐Charlotte Björklund(Karolinska Institutet), Anna Tranberg(Karolinska Institutet), Elena Riva(Humanitas University)
Cited by 0
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739